X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Journal of Hepatocellular Carcinoma

期刊標題檢索 J HEPATOCELL CA 最新評論: It took two months from the first submission to the review process. In... (2024-12-21)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Journal of Hepatocellular Carcinoma]您好,您是該頁面的第 18586 位訪客。

期刊簡介
期刊名稱Journal of Hepatocellular Carcinoma Journal of Hepatocellular Carcinoma
LetPub Score
7.2
50 ratings
Rate

Reputation
8.7

Influence
5.6

Speed
9.6

期刊簡稱J HEPATOCELL CARCINO
ISSN2253-5969
h-indexN.A.
CiteScore
CiteScoreSJRSNIPCiteScore Rank
3.700.8090.790
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Hepatology
Q243 / 88
Category: Medicine
Subcategory: Oncology
Q3229 / 428

自引率 (2023-2024)7.10%自引率趨勢
掲載範囲
官方網站http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journal
在線稿件提交
開放訪問Yes
出版商DOVE MEDICAL PRESS LTD
主題領域ONCOLOGY
出版國/地區NEW ZEALAND
發行頻率
創刊年0
每年文章數216每年文章數趨勢
黃金OA百分比99.65%
OA Related Info
APC: Yes( USD3300; )
APC waiver:Check Notes
Other charges: No
Keywords: hepatocellular carcinoma、cancer、liver cancer、hepatitis b virus
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q2

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ2120/333
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2253-5969%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 16 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Journal of Hepatocellular Carcinoma】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CA-A CANCER JOURNAL FOR CLINICIANSH-index: 144

    CiteScore: 649.80
    NATURE REVIEWS DRUG DISCOVERYH-index: 289

    CiteScore: 159.20
    LANCETH-index: 700

    CiteScore: 92.40
    NEW ENGLAND JOURNAL OF MEDICINEH-index: 933

    CiteScore: 74.80
    Nature Reviews Clinical OncologyH-index: 127

    CiteScore: 126.60
    Nature Reviews Disease PrimersH-index: 48

    CiteScore: 71.30
    NATURE REVIEWS CANCERH-index: 396

    CiteScore: 96.20
    MMWR Recommendations and ReportsH-index: 0

    CiteScore: 131.20
    NATURE REVIEWS IMMUNOLOGYH-index: 351

    CiteScore: 83.50
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONH-index: 622

    CiteScore: 26.00
    學科內最受檢索的期刊 頁面查看次數
    PHARMACEUTICAL BIOLOGY23315447
    Frontiers in Pharmacology6581774
    Oncology Letters1621202
    BIOMATERIALS1581213
    Cancer Medicine1079813
    Oncogenesis1009617
    JOURNAL OF ETHNOPHARMACOLOGY731404
    Archives of Medical Science720673
    MEDICINE711526
    Frontiers in Oncology602504
  •  

    Journal of Hepatocellular Carcinoma Journal of Hepatocellular Carcinoma
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [Journal of Hepatocellular Carcinoma] 的評論撰寫評論
作者: 科研卡拉米


領域: 医学
審稿時間: 4.0 month(s)
結果: 拒稿


撰寫評論

2024-12-21 14:33:46 評論於
It took two months from the first submission to the review process. In the meantime, they asked for the raw data tapes, which took a long time to provide. After another two months, they told me that they had only found one reviewer and rejected my submission directly.
(0) 讚! | 科研卡拉米

作者: WestLBS


領域: 医学
審稿時間: 1.0 month(s)
結果: 拒稿


撰寫評論

2024-10-05 15:54:35 評論於
The difficulties arose when a public database + sample verification combination generated a flurry of emails before and after;
24-9-16 submission
24-9-17 asked me to confirm if ethical approval had been obtained (manuscript clearly stated, I replied that approval had been obtained)
24-9-23 asked why I needed ethical approval for the public database I was using (I clearly stated it was a combination of a database + sample verification, obviously they didn't even read the article and just talked nonsense with me)
24-9-23 the same day asked for the research plan for the clinical sample repository (including inclusion criteria) and the hospital's ethical review approval
24-9-27 asked why the head of the sample repository was not included in the list of authors (replied because the sample repository is shared by the department, not specifically collected for this study)
24-9-30 asked if this study (rather than the clinical sample repository) had obtained ethical approval, I replied that the sample repository used had obtained approval, using the sample repository for research can exempt ethical review and attached relevant regulations
24-10-2 received a template rejection email, the letter did not mention any of the above
I don't know what to say, the article that I urgently wanted to publish, unexpectedly encountered such an editor, sigh
(0) 讚! | WestLBS

作者: 柳叶刀V5


領域: 医学
審稿時間: 6.0 month(s)
結果: 拒稿


撰寫評論

2024-07-19 22:59:30 評論於
After waiting for two months, I was told that they couldn't find reviewers and my submission was rejected.
(0) 讚! | 柳叶刀V5

作者: cmdl


領域: 医学
審稿時間: 1.0 month(s)
結果: 待定&不明


撰寫評論

2021-11-17 15:33:27 評論於
Will articles on bioinformatics and experimental validation be accepted?
(0) 讚! | cmdl

作者: IT测试请忽略


領域: 医学
審稿時間: 1.0 month(s)
結果: 拒稿


撰寫評論

2021-03-09 14:32:38 評論於
The tumor journal is pretty good, why is no one paying attention to it?
(5) 讚! | IT测试请忽略

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [Journal of Hepatocellular Carcinoma] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*